Anzeige
Mehr »
Login
Dienstag, 04.06.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
10 Gründe für ein herausragendes Chance-Risiko-Verhältnis bei dieser Nickel-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema CHEMOMAB THERAPEUTICS LTD.

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
03.05.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer1
07.03.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer1
07.03.Chemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update278-Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025- -Cash Runway Extended through End...
► Artikel lesen
20.02.Chemomab Therapeutics Ltd: Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases159-CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024- -New CM-101 Patents Granted by Brazil and Israel...
► Artikel lesen
03.01.Chemomab Therapeutics, Ltd.: Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024181-Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial- -CM-101's Unique Dual Anti-Fibrotic...
► Artikel lesen
03.01.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer1